Biopharma Daily Stock Updates - 03/16/21

$XBI $145.89 -2% 📉

Covid Updates

$MRNA +9% Doses first patient in ph 2/3 study of covid vaccine in pediatric population. source


Pipeline Updates

$AVXL +9% Ph 3 results of ANAVEX 2-73 in neurodegenerative disorders published in journal of Neuropharmacology. source


$SPPI -4% FDA scheduled a pre-approval inspection of their ROLONTIS manufacturing facility in South Korea in May 2021. In Oct 2020 FDA deferred decision on BLA because inspection could not be conducted due to covid-19 travel restrictions. source


$FGEN -2% Initiate LELANTOS-2, 2nd ph 3 study of pamrevlumab for Duchenne muscular dystrophy. source


$GBT -4% In-licenses 2 early-stage sickle cell disease assets from Sanofi. Mechanism differentiated from Vox support the companies strategy to address SCD. source


$KALA +4% Cigna adds EYSUVIUS 0.25% as a preferred brand on it's commercial formulary. source


$KDNY -7% First patient dosed in ph 3 study of atrasentan for IGA nephropathy. source

0 comments